157 completed, 27 unknown, 15 terminated, 14 recruiting. 230 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 230 | Completed 157, Unknown 27, Terminated 15, Recruiting 14, Withdrawn 11, Not yet recruiting 4, Active not recruiting 2 |
Follow Attention Deficit and Disruptive Behavior Disorders: new trials by email Literature Review of Attention Deficit and Disruptive Behavior Disorders trials Research Report on Attention Deficit and Disruptive Behavior Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Delayed-Release, Extended-Release Methylphenidate (Jornay PM) for Adolescents and Young Adults With Attention-Deficit/Hyperactivity Disorder and Cannabis Use Disorder Delayed-release, extended-release methylphenidate, Placebo - ADHD, Cannabis Use Disorder | Phase 4 | Not yet recruiting | Massachusetts General Hospital | 66 | 2026-11-01 | 2026-09-28 |
| Evaluation of Foquest in Adults 65 Years and Older With ADHD Methylphenidate hydrochloride extended-release capsules - Attention Deficit Hyperactivity Disorder | Phase 4 | Recruiting | Dar Clinical Research Inc. | 36 | 2026-10-06 | 2026-10-07 |
| EEG Biomarkers for ADHD Stimulant Treatment methylphenidate HCl, Mixed amphetamine salts extended release - ADHD | Phase 4 | Not yet recruiting | Boston Children's Hospital | 220 | 2026-09-15 | 2026-06-16 |
| Medication Treatment of ADHD in Pediatric Epilepsy methylphenidate hydrochloride (Jornay PM) - ADHD - Attention Deficit Disorder With Hyperactivity | Phase 4 | Recruiting | Hugo W. Moser Research Institute at Kennedy Krieger, Inc. | 25 | 2026-05-29 | 2026-07-29 |
| Atomoxetine and Executive Function in PTSD Atomoxetine, Placebo - Posttraumatic Stress Disorder With Attention Defic | Phase 4 | Recruiting | VA Office of Research and Development | 160 | 2026-04-01 | 2026-07-07 |
| Predictors of Improvements in Irritability and Aggression in Children With ADHD Treated With CNS Stimulants CNS Stimulant, Placebo, CNS Stimulant open label first phase - ADHD - Attention Deficit Disorder With Hyperactivity, Irritability | Phase 4 | Recruiting | Milton S. Hershey Medical Center | 136 | 2026-03-05 | 2026-04-20 |
| Treating Young Children With Attention Deficit Hyperactivity Disorder Guanfacine (GUA), Methylphenidate (MPH) - Attention-Deficit/Hyperactivity Disorder (ADHD) | Phase 4 | Recruiting | Children's Hospital Medical Center, Cincinnati | 370 | 2026-02-16 | 2026-09-14 |
| The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine Adderall XR (mixed salts amphetamine), Placebo - Attention Deficit Hyperactivity Disorder (ADHD), Autism | Phase 4 | Recruiting | Gagan Joshi | 196 | 2026-02-01 | 2026-03-06 |
| R61/33 - VR Study Phase 4 Meta Quest 3 VR Headset with noise cancelling headphones - Attention Deficit Hyperactivity Disorder | Phase 4 | Recruiting | Rutgers, The State University of New Jersey | 252 | 2025-09-09 | 2026-01-28 |
| PHArmaCokinetics of methYLphenidate in Adult Patients With Attention-Deficit /Hyperactivity Disorder PHArmacoKinetics of methYLphenidate in adult patients with ADHD: comparison between patients with and without OBesity. - Attention Deficit Hyperactivity Disorder (ADHD), Obesity (Body Mass Index &Amp;Amp;gt;30 kg/m2) | Phase 4 | Not yet recruiting | University Hospital, Tours | 30 | 2025-09-01 | 2025-08-13 |
| A Study to Assess the Effectiveness and Safety of Clonidine Extended-Release OnydaTM XR in Children With ADHD and ODD Clonidine extended release oral suspension, Placebo - Attention-deficit/Hyperactivity Disorder, Oppositional Defiant Disorder in Children | Phase 4 | Not yet recruiting | Las Vegas Medical Research, LLC DBA Vector Clinical Trials | 162 | 2025-07-01 | 2025-07-01 |
| An Open-Label Treatment With Randomization Observation, Investigator-Initiated Study, on the Duration and Efficacy of Jornay PM (Methylphenidate Hydrochloride Extended-Release Capsules) on Adult ADHD Symptoms and Executive Function and Emotional Regulation Throughout the Day Into Early Evening Methylphenidate Hydrochloride Extended Release Capsule - Attention-deficit/Hyperactivity Disorder | Phase 4 | Recruiting | NYU Langone Health | 30 | 2025-01-29 | 2026-04-29 |
| A Trial of Dyanavel XR in Treating Co-occurring Fatigue Symptoms in Adults With Attention Deficit Hyperactivity Disorder (ADHD). Dyanavel XR, Placebo - Fatigue, Attention Deficit Hyperactivity Disorder | Phase 4 | Recruiting | Rochester Center for Behavioral Medicine | 50 | 2024-09-01 | 2024-11-21 |
| Multimodal Brain Imaging of Methylphenidate in Children and Adolescents With ADHD Methylphenidate, Placebo - ADHD | Phase 4 | Withdrawn | Johns Hopkins University | 2024-04-16 | 2024-03-15 | |
| Open-label Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD and Mood Symptoms SPN-812 - Attention-Deficit/Hyperactivity Disorder | Phase 4 | Completed | Supernus Pharmaceuticals, Inc. | 161 | 2024-03-25 | 2026-03-27 |
| Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD 100mg SPN-812, Placebo - Attention-Deficit/Hyperactivity Disorder | Phase 4 | Recruiting | Supernus Pharmaceuticals, Inc. | 286 | 2024-03-19 | 2026-10-05 |
| Methylphenidate for the Treatment of PTSD With Associated Neurocognitive Complaints Methylphenidate, Placebo - Posttraumatic Stress Disorder (PTSD) | Phase 4 | Recruiting | VA Office of Research and Development | 70 | 2024-02-05 | 2026-08-19 |
| Duration and Efficacy of Azstarys on Adult ADHD Symptoms and Executive Function in Early Evening Serdexmethylphenidate/dexmethylphenidate - Adult Attention Deficit Hyperactivity Disorder | Phase 4 | Completed | NYU Langone Health | 29 | 2023-11-13 | 2025-07-29 |
| AWARE: Management of ADHD in Autism Spectrum Disorder Randomization to either Amphetamine (AMP) class of stimulant medication or Methylphenidate (MPH) class of stimulant medication, Randomization to either Alpha 2 agonist class of medication or alternate class of stimulant. - ADHD, Autism Spectrum Disorder | Phase 4 | Recruiting | Daniel Coury | 500 | 2023-10-01 | 2026-10-22 |
| A Safety/Tolerability and PK Study With Azstarys® in Children With ADHD Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH) - Attention Deficit/Hyperactivity Disorder | Phase 4 | Completed | Corium, Inc. | 123 | 2023-06-02 | 2026-05-08 |
Showing 20 of 230. Sign in to see all of them.
Attention Deficit Disorder with Hyperactivity (225) · Conduct Disorder (9) · Substance-Related Disorders (9) · Aggression (7) · Oppositional Defiant Disorder (7) · Autistic Disorder (6) · Spasm (5) · Autism Spectrum Disorder (4) · Bipolar Disorder (4) · Dyslexia (4) · Anxiety Disorders (3) · Asperger Syndrome (3) · Brain Injuries, Traumatic (3) · Child Development Disorders, Pervasive (3) · Epilepsy (3)
Mental Disorders (230) · Neurodevelopmental Disorders (229) · Nervous System Diseases (21) · Pathological Conditions, Signs and Symptoms (16) · Signs and Symptoms (16) · Behavior (14) · Neurologic Manifestations (14) · Chemically-Induced Disorders (12) · Behavioral Symptoms (9) · Aberrant Motor Behavior in Dementia (7) · Brain Diseases (7) · Central Nervous System Diseases (7) · Social Behavior (7) · Child Development Disorders, Pervasive (6)
Methylphenidate (92) · Atomoxetine Hydrochloride (49) · Lisdexamfetamine Dimesylate (26) · Guanfacine (12) · 5,10-dihydro-5-methylphenazine (7) · Sugars (7) · Amphetamine (6) · Central Nervous System Stimulants (6) · Dexmethylphenidate Hydrochloride (6) · SLI381 (6) · Aripiprazole (5) · Dextroamphetamine (5) · Risperidone (5) · Adderall (4) · Naltrexone (4)
Eli Lilly and Company (23) · Massachusetts General Hospital (23) · Children's Hospital Medical Center, Cincinnati (7) · Shire (7) · NYU Langone Health (6) · Icahn School of Medicine at Mount Sinai (5) · Federal University of Rio Grande do Sul (4) · Florida International University (4) · Hospital de Clinicas de Porto Alegre (4) · JPM van Stralen Medicine Professional (3) · Milton S. Hershey Medical Center (3) · New York State Psychiatric Institute (3) · Ortho-McNeil Janssen Scientific Affairs, LLC (3) · Pfizer (3) · Rhodes Pharmaceuticals, L.P. (3)
United States (145) · Canada (17) · Netherlands (12) · Brazil (10) · Germany (8) · Sweden (7) · China (5) · South Korea (5) · Israel (4) · Puerto Rico (4) · Australia (3) · Belgium (3) · Spain (3) · Taiwan (3) · United Kingdom (3)
Joseph Biederman, MD (7) · Ann Childress, MD (6) · Jeffrey Newcorn, MD (6) · Timothy Wilens, MD (5) · Lenard Adler, MD (3) · Paul Hammerness, MD (3) · Thomas Spencer, MD (3) · Eugenio Grevet, PhD (2) · Gagan Joshi, MD (2)
PMID 25019647, PMID 37811711, PMID 21569378, PMID 24290461, PMID 26745211, PMID 28980198, PMID 35201607, PMID 37058600, PMID 10591283, PMID 10591284, PMID 10637676, PMID 10637677, PMID 11104313, PMID 11104315, PMID 11104317, PMID 11211363, PMID 11211364, PMID 11211365, PMID 11211366, PMID 11211367, PMID 11294072, PMID 12014781, PMID 12108764, PMID 12795577, PMID 12880507, PMID 14595084, PMID 14998110, PMID 15060225, PMID 15677282, PMID 15685125, PMID 15827573, PMID 16135621, PMID 16350601, PMID 16371674, PMID 16418159, PMID 16671928, PMID 16881772, PMID 17053977, PMID 17448997, PMID 17667478, PMID 17667479, PMID 17667480, PMID 17667481, PMID 17710545, PMID 18573923, PMID 18573924, PMID 18759644, PMID 19142107, PMID 19192455, PMID 19307987
2014 (2), K24DA016264 (2), 2009 (1), 2015 (1), 2018 (1), 2019 (1), I01RX004823 (1), K12DA000357 (1), K23MH064975 (1), K23MH066127 (1), K23MH066835 (1), K23MH083881 (1), M01RR010710 (1), P30MH066386 (1), P50MH077248 (1)